Neuroscientist | Scientific Consultant in Physics & Theoretical Biology | Author & Co-founder at VMeDx
Answered 9 months ago
Good Day, New evidence indicates that mild increases in hs-cTnT and NT-proBNP, two cardiac biomarkers, predict cancer risk even in people who have no heart disease. This could change the game in the early detection of cancer. Generally used as measures for heart health, these markers could now identify patients more at risk for certain types of cancer, including lung and colorectal. These biomarkers can also help identify those seemingly healthy patients who need to be screened closely or given early screening. It strengthens the message on the importance of common shared risk factors such as inflammation, cigarette smoking, and obesity. When used widely, these biomarkers will facilitate early cancer detection when the disease is most treatable. If you decide to use this quote, I'd love to stay connected! Feel free to reach me at gregorygasic@vmedx.com and outreach@vmedx.com.
As the founder of a health support organization dedicated to helping improve U.S. healthcare through patients, I believe there is tremendous promise in recent research connecting cardiac blood markers and cancer risk. The advance, featured in a UCLA Health research, demonstrates for the first time that small elevations in biomarkers for heart disease, including high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), are linked to an increased risk of developing cancer, particularly lung and colorectal cancers, in diverse populations of patients who initially did not have any symptoms of heart disease. By integrating these widely available tests into routine screenings, healthcare providers can identify at-risk patients early, allowing targeted strategies to prevent the disease. For instance, a person with high NT-proBNP might be recommended for early lung cancer screening, which could detect cancer earlier than it would be evident through symptoms or clinical tests. This discovery empowers my organization to advocate for interdisciplinary care models blending cardiology and oncology. We can work toward pushing updated guidelines that incorporate these biomarkers into primary care evaluations, especially in high-risk groups like smokers or those with obesity. Teaching patients common risk factors, like an unhealthy diet and a sedentary lifestyle, may change some behaviors, reducing both heart disease and cancer incidence. With 6,244 participants in the study showing a clear link, we can confidently promote proactive screening to save lives.
Having analyzed genomic and clinical data from over 135,000 NHS patients through our work with Genomics England, I can tell you this connection between cardiac markers and cancer risk represents a massive opportunity for early intervention. We've seen similar patterns in our federated datasets where seemingly unrelated biomarkers reveal shared biological pathways between diseases. The real game-changer here is implementing real-time monitoring systems that can flag these cardiac biomarkers during routine care. In our lung cancer genetics study with 23andMe, we're already seeing how AI-driven analytics can identify risk patterns before symptoms appear. Healthcare systems need to integrate these cardiac markers into their existing screening protocols—not as separate tests, but as part of comprehensive risk assessment algorithms. From a practical standpoint, this means your annual cardiac panel could simultaneously screen for cancer risk using the same blood draw. We've built federated systems that can analyze these multi-disease patterns across hospital networks without moving sensitive patient data. The key is having AI systems that can process these complex biomarker relationships in real-time during clinical visits. The biggest impact will come from updating clinical decision support systems to include these cardiac-cancer risk correlations. When a cardiologist sees liftd markers, the system should automatically flag the patient for improved cancer surveillance. This requires the kind of federated data infrastructure we've deployed across multiple health systems—where insights can be shared while keeping patient data secure.
In our adolescent healthcare program, we're already seeing how interconnected different health systems are, and this research reinforces the importance of comprehensive health screenings. When working with teens who have family histories of either cancer or heart disease, I've started recommending they talk to their primary care doctors about monitoring both conditions. This connection between heart markers and cancer risk shows us why mental health professionals need to stay informed about physical health developments to provide truly holistic care.
At Thrive, we've seen how interconnected health conditions manifest in unexpected ways—patients presenting with anxiety often have underlying autoimmune markers that surface months later. This cardiac-cancer connection validates what we've observed in our behavioral health practice: the body's stress response systems create cascading effects across multiple organ systems. The practical application lies in reframing routine mental health assessments to include physical health monitoring. When we implemented comprehensive wellness screenings at Thrive, we finded that 40% of our patients with persistent anxiety had liftd inflammatory markers that warranted medical follow-up. This holistic approach caught several underlying conditions before they became critical. Healthcare systems need to break down silos between specialties immediately. At Lifebit, our federated architecture allows mental health providers to seamlessly share relevant biomarker data with cardiologists and oncologists without compromising patient privacy. A patient's stress-related cardiac changes during behavioral health treatment could now trigger proactive cancer screening protocols. The behavioral health implications are huge—patients with liftd cardiac markers linked to cancer risk will need immediate psychological support for the anxiety this creates. We're already developing care pathways that address both the physical monitoring requirements and the mental health impact of living with increased disease risk.
This finding highlights the growing importance of integrated diagnostics. It is not just a medical advancement but a clear sign that healthcare providers and suppliers must consider it from a broader perspective. If a cardiology test can indicate a future cancer risk, then hospitals should update protocols and invest in tools that offer cross-functional value. This shift calls for greater collaboration between cardiology, oncology, and diagnostic teams. When departments share insights and act on early signals, they improve patient outcomes while reducing unnecessary resource use. Early intervention benefits the entire system, from clinical decision-making to operational planning and making care more efficient, precise, and responsive.
Absolutely, this new research is quite a game-changer for those of us in healthcare. If you think about it, finding a link between cardiac markers and cancer risk could really revolutionize how we approach preventive care. By using routine cardiac assessments to not only check for heart issues but also to gauge cancer risk, doctors can develop more comprehensive care plans way ahead of time. For instance, in my own practice, this kind of information would allow us to intervene earlier. We could tailor lifestyle advice and screening more closely to each individual's risk profile, potentially catching serious conditions before they fully develop. And it’s not just about early detection; this could also impact the guidelines for regular health screenings, making them more personalized and, ultimately, more effective. This stride in research gives us as healthcare providers another tool in our kit to help understand the bigger picture of a patient's health before problems start showing up. It's all about staying one step ahead.